SCHEMBL12796398

SCHEMBL12796398

O=C(c1cnc(N[C@@H]2C[C@H]3CC[C@@H]2O3)nc1C(F)(F)F)N1CCC(F)(F)CC1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SCD O00767 1/20 0.39
▸ CXCR4 P61073 1/20 0.37
▸ VNN1 O95497 2/20 0.35
▸ PDE5A O76074 1/20 0.34
▸ PDE9A O76083 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ CNR2 P34972 7/20 0.34
▸ SYK P43405 3/20 0.34
▸ CYP2D6 P10635 2/20 0.34
▸ CYP2C19 P33261 2/20 0.34
▸ CYP1A2 P05177 2/20 0.34
▸ LRRK2 Q5S007 1/20 0.34
▸ CYP2C9 P11712 2/20 0.33
▸ MAPK8 P45983 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ PLAT P00750 1/20 0.33
▸ NR1H2 P55055 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12796397 0.95 VNN1 (0.37) SCDCXCR4VNN1PDE5APDE9A
SCHEMBL12796381 0.89 LRRK2 (0.41) SCDCXCR4CNR2SYKCYP2D6
SCHEMBL541416 0.89 CXCR4 (0.37) SCDCXCR4VNN1PDE5APDE9A
SCHEMBL12796373 0.89 LRRK2 (0.41) SCDCXCR4CNR2SYKCYP2D6
SCHEMBL12796394 0.89 CXCR4 (0.37) SCDCXCR4VNN1PDE5APDE9A
SCHEMBL12796366 0.87 CXCR4 (0.37) SCDCXCR4PDE5APDE9ACNR2
SCHEMBL12796374 0.87 CXCR4 (0.37) SCDCXCR4PDE5APDE9ACNR2
SCHEMBL12796026 0.82 PDE5A (0.44) PDE5APDE9ACNR2CYP2D6CYP2C19
SCHEMBL12796021 0.82 PDE5A (0.44) PDE5APDE9ACNR2CYP2D6CYP2C19
SCHEMBL12795985 0.80 MAPT (0.47) PDE5APDE9AALDH1A1CNR2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130310373-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-11-21 — — US disclosed
US-8524727-B2 Pyrimidine compound ASTELLAS PHARMA INC. (JP) 2013-09-03 — — US disclosed
US-8524727-B2 Pyrimidine compound ASTELLAS PHARMA INC. (JP) 2013-09-03 — — US disclosed
US-20110053912-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-03-03 — — US disclosed
US-20110053912-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-03-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053912-A1 PYRIMIDINE COMPOUND CNR2, CNR1, P2RY2 SCD 1093/4885CXCR4 350/4885VNN1 3256/4885
US-20130310373-A1 PYRIMIDINE COMPOUND CNR2, CNR1, P2RY2 SCD 1251/4885CXCR4 206/4885VNN1 2974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback